Prescriptions; creating the Oklahoma Health Care Safety Net and Affordable Prescriptions Accessibility Act; prohibiting certain actions; providing for enforcement by Attorney General and Insurance Commissioner. Effective date.
SB 1063 creates the “Oklahoma Health Care Safety Net and Affordable Prescriptions Accessibility Act,” a state law aimed at protecting 340B-covered entities and their contract pharmacies from reimbursement and contracting practices that the bill defines as discriminatory. The measure bars health insurers, pharmacy benefit managers (PBMs), and other third-party payors from paying 340B entities less than comparable non-340B entities for the same drug, imposing special fees, audits, claim modifiers, network restrictions, or other burdens tied to 340B status, or otherwise interfering with a patient’s ability to obtain prescriptions from a 340B entity.
The bill also prohibits manufacturers and distributors from denying, restricting, or interfering with the acquisition or delivery of 340B drugs to contract pharmacies authorized to dispense on behalf of covered entities, unless federal law or HHS rules require otherwise. It gives enforcement authority to the Attorney General and the Insurance Commissioner, including rulemaking, license discipline, and civil fines of $100 to $10,000 per violation. The bill expressly excludes Oklahoma Medicaid reimbursement rules where federal Medicaid drug law applies and states that it should not be read to conflict with federal law or more restrictive federal requirements.
If enacted, SB 1063 would add new provisions to Title 36 of the Oklahoma Statutes governing prescription drug reimbursement and contracting practices involving 340B entities, PBMs, insurers, and drug manufacturers/distributors. It would create enforceable state protections for hospitals, clinics, and pharmacies participating in the federal 340B drug discount program, while limiting the ability of payors and manufacturers to impose 340B-specific conditions or network exclusions. The bill would also expand regulatory and enforcement authority for the Attorney General and Insurance Commissioner over covered entities and licensed persons under Oklahoma insurance laws.
The available record shows no committee transcript or recorded votes, so there is no documented floor or committee debate to gauge support or opposition. Based on the bill’s structure and purpose, it appears designed to support safety-net providers and preserve access to discounted prescription drugs, suggesting a pro-provider and pro-patient-access policy orientation. The absence of recorded opposition in the provided materials means sentiment cannot be measured directly from debate, but the bill’s language indicates an intent to address perceived barriers imposed by PBMs, insurers, and manufacturers on 340B participants.
The main points of contention likely involve whether the bill intrudes on PBM and insurer reimbursement practices, whether it creates compliance and administrative burdens, and whether its restrictions on manufacturer and distributor conduct are preempted by federal law. The bill itself anticipates legal tension by stating that it should not be construed to conflict with federal law and by carving out Medicaid and federally required limited-distribution arrangements. Potential opponents would likely be health insurers, PBMs, and drug manufacturers/distributors; likely supporters would be 340B hospitals, clinics, contract pharmacies, and patient-access advocates.